Why a focal cartilage defect is not the same as end-stage knee disease

Being told you have a cartilage defect in your knee is not the same as being told you need a knee replacement — even if both phrases come up in the same conversation. The two conditions sit on entirely different points of the disease ladder, and treating them as equivalent leads patients either to unnecessary surgery or to a missed window for joint preservation.

A focal chondral defect is a localised, full-thickness patch of cartilage damage within an otherwise reasonably intact knee. The surrounding joint space is preserved, the bone structure is largely sound, and only one discrete area of the articular surface has broken down. Knee replacement, by contrast, addresses end-stage bone-on-bone osteoarthritis — wear that has spread across the whole or the majority of the joint compartment, where preservation is no longer viable.

The critical caveat is that a focal defect, left alone, rarely stays localised. Cartilage has negligible capacity for self-repair owing to its very limited blood supply; without intervention, the damaged patch tends to enlarge and the mechanical load it sheds onto surrounding tissue accelerates degeneration. That progression is the primary pathway from a discrete lesion to the generalised osteoarthritis that eventually makes joint replacement necessary.

This creates a meaningful decision window — a period in which the joint is still structurally preservable and options exist that neither simply mask symptoms nor permanently replace the knee. What sits in that window, and who belongs in it, is what this article addresses.

How ChondroFiller works as an injectable collagen scaffold

ChondroFiller — marketed in the UK as Liquid Cartilage — is a CE-marked Class III medical device: an acellular scaffold of injectable Type I collagen, supplied as a liquid and placed directly into a mapped cartilage defect.

In the current service pathway, it is delivered via ultrasound-guided outpatient injection — no theatre admission, no surgical incisions, no general anaesthetic. Once inside the joint, the liquid self-gels within approximately 3–5 minutes, forming a three-dimensional collagen matrix that conforms to the contours of the defect.

What follows is the process described as acellular matrix-induced chondrogenesis. The scaffold itself contains no cells; it is a structural framework. The patient's own progenitor cells — drawn from the surrounding synovium and the subchondral bone beneath the defect — migrate into the matrix, differentiate into chondrocytes, and begin producing repair tissue. The body does the biological work; the scaffold organises the environment in which that work takes place. This is a meaningful distinction from the idea that the injection simply regrows cartilage: rather, it supports the body's own repair processes by providing an architecture those processes would otherwise lack.

Over the 12–24 months following injection, the collagen scaffold resorbs progressively as repair tissue matures, leaving no permanent foreign material in the joint.

ChondroFiller carries CE marking and is clinically available in the UK and across Europe. It does not currently hold FDA approval; published clinical outcome data comes from European patient cohorts.

Who the injection pathway suits and who it does not

The injection pathway suits patients with a Grade III or IV focal chondral defect — cartilage lost through more than half its thickness or eroded to the bone beneath — covering an area of up to approximately 6 cm², within a knee that otherwise retains reasonable structural integrity. Most clinical cases involve defects up to 3 cm², though the manufacturer's clinical evidence report supports the wider indication in suitable joints.

MRI is not an optional step before this treatment — it is the essential one. Defect size, depth, and the condition of the surrounding cartilage and subchondral bone cannot be reliably assessed through clinical examination alone. Lincolnshire Knee uses AI-assisted cartilage segmentation and mapping to support this assessment, helping to clarify whether a lesion genuinely qualifies as focal or represents more widespread degeneration.

Age, on its own, is not a barrier. Active patients in their 60s and 70s with a discrete focal lesion may be suitable candidates — including those who have already been advised toward joint replacement. If the defect is genuinely localised and the surrounding joint remains structurally sound, the decision framework is the same as for a younger patient.

The pathway does have clear limits. Generalised osteoarthritis, bone-on-bone wear distributed across the joint, or advanced bi- or tri-compartmental disease all place a patient outside candidacy — the surrounding cartilage has broken down too widely for a focal scaffold to provide meaningful benefit. Joint replacement, partial or total, remains the appropriate pathway for end-stage disease. ChondroFiller sits earlier on that ladder: a joint-preservation option for patients who still have something worth preserving, not a substitute for arthroplasty once that window has closed.

What clinical outcomes show at 12 months and beyond

The strongest available evidence comes from the manufacturer's April 2025 Clinical Evaluation Report (CER), which consolidates data from four distinct knee-specific clinical studies. Across all four, IKDC scores improved by approximately 30 points over 12 months — a number that carries weight in context: the minimum clinically important difference for IKDC is 16.7 points, the threshold below which most patients would not describe a meaningful change in their knee. These results consistently exceed that threshold.

Structural repair quality shows a comparable pattern. MOCART scores — a validated MRI-based measure of defect filling and cartilage integration — range from 81.6 to 84.3, indicating more than 80% defect fill and good integration with the surrounding native cartilage. Progression is visible in the imaging data: MOCART averaged 65.3 at four weeks, rising to 81.6 by one year — consistent with gradual tissue maturation rather than an immediate structural change.

The longest available follow-up comes from the Jerosch et al. prospective PMCF study, which tracks patients to three years. Mean IKDC improvement reached 32.4 points by that point, with patients arriving at a mean IKDC of 80 — a functional level associated with good everyday knee performance and a return to moderate physical activity. Independent peer-reviewed corroboration comes from Simeonov's 2024 study in the Journal of IMAB, which used both the Lysholm scale and IKDC at 12 months in 17 knee patients and reported improvements in both measures. The reported complaint rate across the CER dataset is approximately 0.06%, consistent with a low adverse-event profile.

Long-term comparative data against knee replacement — particularly in borderline cases with Grade IV lesions and early diffuse joint change — does not yet exist. No randomised trial of ChondroFiller versus arthroplasty has been completed. The three-year Jerosch findings are the furthest published follow-up currently available.

ChondroFiller against the wider treatment ladder

The treatment landscape for focal knee cartilage defects spans from symptom management to joint replacement. Each option occupies a different position on that ladder, and the injectable collagen scaffold sits at a genuinely distinct point along it.

Corticosteroid injections have a legitimate role in acute inflammatory flares and short-term pain control — including as a bridging measure before a planned procedure. The concern with repeated use is structural: a published meta-analysis found intra-articular corticosteroids for knee osteoarthritis were associated with significantly greater odds of cartilage structure worsening on imaging (OR 2.01, 95% CI 1.18–3.44). That is a reason to discuss long-term injection plans carefully with a clinician, not a reason to avoid a single well-indicated injection. Hyaluronic acid viscosupplementation reduces symptoms in some patients and carries conditional guideline support, though bodies including AAOS and ACR have remained more sceptical. Neither approach restores cartilage — both are palliative tools.

Arthroscopic cartilage surgery sits further along the ladder. Microfracture and mosaicplasty are established options for smaller defects under 2–4 cm², and both require operative theatre admission. A 2021 systematic review found microfracture yields inferior clinical outcomes in middle-aged patients compared with younger cohorts — relevant for a cohort that may present at exactly the stage where the injectable route is being considered. For defects of 3 cm² and above, MACI has demonstrated improved KOOS pain and function scores versus microfracture at 2 and 5 years in the SUMMIT trial. Its results can be durable, but MACI is a two-stage pathway: cartilage is harvested arthroscopically in a first procedure, cells are cultured in a laboratory, and a second operation implants the matrix.

ChondroFiller as an ultrasound-guided injectable collagen scaffold occupies the gap between these two groups — more structurally targeted than any conventional joint injection, and substantially less invasive than any cartilage surgery on the ladder above it. No bone drilling, cell harvesting, or theatre admission is required. Surgical options remain valid for patients whose defect size or stage calls for them; the question is matching the right intervention to the right stage.

Getting assessed at Lincolnshire Knee

For patients weighing a joint-preservation route against arthroplasty, a structured assessment does more than confirm a diagnosis — it maps the specific variables that determine which path makes clinical sense: defect dimensions, cartilage quality in the adjacent compartments, joint alignment, and the overall structural picture that no symptom questionnaire can supply. This is the clinical groundwork that converts a general question about treatment options into a specific, defensible recommendation for or against the injectable scaffold pathway.

Lincolnshire Knee, part of the MSK Doctors group, offers consultant-led assessment at two sites: Sleaford NG34 — the group's head office, housing an Open MRI suite and Regeneration Hub — and Grantham NG31 for consultation and diagnostics. The clinic accepts patients directly, without a GP referral and without NHS-style waiting times: a practical consideration for anyone who has reached a decision-making point and does not wish to wait months for a first conversation.

To arrange an assessment, visit lincolnshireknee.co.uk.

1. [1] A Systematic Review of Focal Cartilage Defect Treatments in Middle-Aged Versus Younger Patients. (2021). https://doi.org/10.1177/23259671211031244 https://doi.org/10.1177/23259671211031244